Roche Holding AG Virtual Early Drug Development gRED Call Transcript
Ladies and gentlemen, welcome to the Roche Virtual Early Drug Development gRED Event 2020 Conference Call. I am Sandra, the Chorus Call operator. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to Karl Mahler, Head of Investor Relations and Roche Group Planning. Please go ahead, sir.
Yes. Thanks a lot, Sandra. Good afternoon, good morning, ladies and gentlemen. Warm welcome from our side here from Basel. This is actually the second event we do for those -- for these kind of more fundamental insights into the Roche, where we had one done for pRED a few weeks ago. We will have one in May on digital -- digitization. And today, we want to focus on Genentech's early research and development known as gRED.
We have with us today Mike Varney. He is the Head of Genentech Research and Early Development of the entire setup. He will give us an overview and strategic insights. We have Andy Chan with us for the non-oncology
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |